Clinical Projects
Clinical trials are currently ongoing at the Tallaght Adult Mental Health Service, Sheaf House, Exchange Hall, Belgard Square North, Dublin 24 and the Wellcome-HRB Clinical Research Facility at St James's Hospital, Dublin 8.
Industry Sponsored clinical trials:
In partnership with:
1. BioDepTT: Biobank for Depression, Tallaght University Hospital and Trinity College Dublin
BioDepTT is a research project led by Trinity College Dublin and Tallaght University Hospital, aiming to improve how we understand and treat depression.
The project brings together volunteers who are willing to share health information and biological samples, helping to build a clearer picture of how depression affects people in different ways. This information is stored securely in a biobank and used by our research team to explore new ways to diagnose, treat, and support people living with depression.
Participation is entirely voluntary, and all data is handled with the highest standards of care and confidentiality.
By taking part, you can make a meaningful contribution to mental health research and help shape better care for the future.
Interested in participating? Contact team at: kellyj37@tcd.ie
2. Helus EMBRACE: A Phase 3 Trial to Assess HLP003 in Major Depressive Disorder
The purpose of the EMBRACE clinical trial is to evaluate an investigational study medicine called HLP003 combined with psychological support in people who are taking a single antidepressant medication, to learn how effective it might be at reducing symptoms of Major Depressive Disorder.
The investigational study medicine HLP003 is similar to psilocin (the active psychedelic
ingredient in Psilocybe mushrooms). This study is being conducted in eight countries and will involve about 330 participants worldwide.
This is a double-blind, placebo-controlled trial, which means that neither you nor your study doctor would know if you are taking the study medicine or a placebo. A placebo looks like the study medicine but does not contain any active ingredient.
Participation in the study will last up to four and a half months, which includes a screening period, a six-week treatment period (with two dosing sessions) and six-week follow-up period.
Participation is entirely voluntary, and all data is handled with the highest standards of care and confidentiality.
EU CT 2024-519270-40-00
Sponsored by Helus Pharma (formerly Cybin Inc.).
Interested in participating? Contact team at: kellyj37@tcd.ie